Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Interest of continuing systemic chemotherapy or not , after a short initial treatment (6
weeks) in patients who are in response or stable disease("Discontinuation design ")of
patients with metastatic oesophageal cancer of squamous cell type
The secondary aims would be to study : toxicity, the overall survival rate, a study of costs
and quality of life.